{"filing":{"accession_number":"0001193125-26-361895","cik":"0001761918","ticker":"ERAS","company_name":"Erasca, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"eras-20260824.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/eras-20260824.htm"},"events":[{"id":29073,"run_id":26602,"accession_number":"0001193125-26-361895","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The FDA's grant of Fast Track Designation (FTD) to ERAS-0015 for metastatic pancreatic adenocarcinoma is a material regulatory milestone that accelerates the development and review pathway for a key product candidate. While FTD does not guarantee approval, it represents a significant operational and strategic achievement for a clinical-stage biopharmaceutical company, potentially expediting the path to market and supporting the company's planned Phase 3 trial initiation. This is a regulatory/operational event that does not fit the specific categories of earnings, M\u0026A, impairment, or other named types, making operational_other the most appropriate classification.","company_name":"Erasca, Inc.","ticker":"ERAS","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31228,"accession_number":"0001193125-26-361895","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA's grant of Fast Track Designation (FTD) to ERAS-0015 for metastatic pancreatic adenocarcinoma is a material regulatory milestone that accelerates the development and review pathway for a key product candidate. While FTD does not guarantee approval, it represents a significant operational and strategic achievement for a clinical-stage biopharmaceutical company, potentially expediting the path to market and supporting the company's planned Phase 3 trial initiation. This is a regulatory/operational event that does not fit the specific categories of earnings, M\u0026A, impairment, or other named types, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:15:49.621974+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31228,"accession_number":"0001193125-26-361895","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA's grant of Fast Track Designation (FTD) to ERAS-0015 for metastatic pancreatic adenocarcinoma is a material regulatory milestone that accelerates the development and review pathway for a key product candidate. While FTD does not guarantee approval, it represents a significant operational and strategic achievement for a clinical-stage biopharmaceutical company, potentially expediting the path to market and supporting the company's planned Phase 3 trial initiation. This is a regulatory/operational event that does not fit the specific categories of earnings, M\u0026A, impairment, or other named types, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:15:49.621974+00:00","company_name":"Erasca, Inc.","ticker":"ERAS","filing_date":"2026-08-24"}]}